Li Peng, Ph.D.

Chief Scientific Officer at Palleon Pharmaceuticals

Li Peng is Chief Scientific Officer of Palleon Pharmaceuticals, a leading biotechnology company developing drugs that target glycan-mediated immune regulation to treat cancer and inflammatory diseases. Li has led the invention of EAGLE, CONVERGENCE, and HYDRA platform technologies and overseen research and early development at Palleon. Prior to joining Palleon, Li had worked at Medimmune/AstraZeneca for ten years in roles of increasing responsibility. She has published ~30 scientific papers and is an inventor on ~30 patents and patent applications. Li has earned a doctorate in biochemistry and molecular biology from the University of California, Davis.